1. Medtech Insight
  2. >>Geography
  3. >>North America
  4. >>United States

FDA Will Not Broadly Release Report Criticizing EU Oversight

The agency decided not to widely disseminate a report examining 12 high-risk devices that were approved in Europe, but were later found to be dangerous or ineffective.

FDA has decided not to broadly release a recently finalized internal report that strongly criticizes the European decentralized device regulatory system for allowing “unsafe” products onto the market.

The report – “Unsafe and Ineffective Devices Approved in the EU That Were Not Approved in the U.S.”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Real-World Evidence Can Help Overcome Regulatory and Market Barriers for Pediatric Medical Devices

 
• By Elizabeth Orr

At AdvaMed’s MedTech Conference in San Diego, speakers brainstorm ways to bring devices to treat children to market more quickly through creative collaboration, better use of real-world data, and taking advantage of ‘low-hanging fruit’ like expanded size ranges.

AdvaMed Warns Of Challenges With Remote Devices While Noting Their Potential

 
• By Brian Bossetta

Though the advance of remote medical device technology allows for better at-home care, it comes with challenges and risks, says AdvaMed, which has published a safety bulletin guiding stakeholders on the operation of remote devices.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

After Success Of Early Alert Pilot, FDA Builds Out Program To Include All Devices

 
• By Brian Bossetta

The US FDA’s device center says the pilot program launched last year to streamline its recall process has been a success. It’s now starting to build off the program’s achievements, which means patients could be aware of potential safety issues from more types of devices.

More from North America

Whistleblower Suit Against UnitedHealth Continues After Semler, Bard Settle Related Cases

 
• By Elizabeth Orr

Insurance firm UnitedHealth is facing allegations the company intentionally used an unreliable PAD screening method to increase its reimbursements under Medicare Advantage. Semler Scientific and Bard, which respectively made and manufactured the products in question, settled related cases for $37m.

‘Much-Needed Tool For Large Tissue Biopsy’: Resitu Medical’s Breast Device FDA Authorized

 
• By Natasha Barrow

Resitu Medical has received FDA 510(k) authorization for the RESL09 breast cancer biopsy device. This handheld minimally invasive device excises tissue samples with diameters up to 9 mm and will first reach market in the US. The company plans to expand the tool’s clinical claims and core size range.

A Clearer Future For Nearsighted Children? FDA Authorizes Novel Eyeglass Lens To Correct Myopia

 
• By Brian Bossetta

The US FDA authorization of the Stellest eyeglass lens from French firm EssilorLuxottica could be game-changing for children with myopia, or nearsightedness. The lenses are designed to slow myopia’s progression in children aged 6 to 12.